My recent biopsy shows no evidence of a new BRAC1/2 mutation so the PARB inhibitors are not an option for me as a new castration resistant metastatic prostate cancer patient.
Made the decision to remain in Phoenix to enter a clinical trial with the Mayo Clinic this month. They were kind enough to hold off closing phase 1 for one more patient. Myself. So 2 days of infusions every 2 weeks until it does not work anymore or I can’t tolerate the side effects. A new drug called PT-112 paired with immunotherapy agent avelumab. Hopefully this study will broaden our armory in the future.
Written by
Cleodman
To view profiles and participate in discussions please or .
Thanks for participating. As you probably know, carboplatin+cabazitaxel was more effective than cabazitaxel alone in a recent Phase 2 clinical trial, so there is hope for some novel platins, expecially when combined with an immune checkpoint inhibitor. They seem to be expanding soon to Phase 2 trials:
I am so relieved to hear the news! I have to admit that I've been in the "bargaining" phase regarding your story, hoping that there would be something else you could try. Wishing that we had a better compassionate use law here that would allow lower doses of 177Lu to avoid the pain you went through. But this is good news and I wish you the best and thank you for exploring the roads not yet taken by most of us.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Clinical Trials
Clinical Trials
Blood transfusions dependent/clinical trials.
Clinical Trials
Treatment naïve and clinical trials
